Clinical Trials

    Showing 1 - 5 of 5 Endometrial Cancers

    Status: Enrolling

    Investigator: Pedro Ramirez

    Study Coordinator: Jaya Kamath

    Phone: 713.441.6616

    The purpose of this study is to evaluate the efficacy and safety of selinexor as a maintenance treatment in patients with p53 wt endometrial carcinoma (EC), who have achieved a partial response (PR) or complete response (CR) (per Response Evaluation ... Read more >

    Status: Enrolling

    Investigator: Behrouz Zand

    Study Coordinator: Jaya Kamath

    Phone: 713.441.6616

    Endometrial cancer (EC) is the most common gynaecological cancer. Current treatment of EC typically includes removal of the uterus and to determine the extent of the disease (removal of fallopian tubes, ovaries & if required a lymph node dissection (... Read more >

    Status: Open Not Enrolling

    Investigator: Tarrik Zaid

    Study Coordinator: Jaya Kamath

    Phone: 713.441.6616

    The purpose of this study is to determine the safety, tolerability, and preliminary efficacy of pembrolizumab/vibostolimab co-formulation (MK-7684A) with or without other anticancer therapies in participants with selected advanced solid tumors. The p... Read more >

    Status: Enrolling

    Investigator: Pedro Ramirez

    Study Coordinator: Jaya Kamath

    Phone: 713.441.6616

    Researchers are looking for new ways to treat people with endometrial cancer (EC) who have previously received treatment with platinum based therapy (a type of chemotherapy) and immunotherapy. Immunotherapy is a treatment that helps the immune system... Read more >

    Status: Enrolling

    Investigator: Aparna Kamat

    Study Coordinator: Jaya Kamath

    Phone: 713.441.6616

    This phase II/III trial tests whether adding trastuzumab and hyaluronidase-oysk (Herceptin Hylecta [TM]) or pertuzumab, trastuzumab and hyaluronidase-zzxf (Phesgo [TM]) to the usual chemotherapy (paclitaxel and carboplatin) works to shrink tumors in ... Read more >